Unlimit Health (formerly SCI Foundation)

What Unlimit Health (formerly SCI Foundation) does

Unlimit Health (formerly SCI Foundation) is a UK-registered international charity founded in 2002 that supports the elimination of parasitic worm infections — primarily schistosomiasis, soil-transmitted helminthiasis, female genital schistosomiasis (FGS), and pork tapeworm (taeniasis) — across 8 sub-Saharan African countries. The organisation works through national Ministries of Health to deliver mass drug administration (MDA), health systems strengthening, monitoring and evaluation, and operational research, having delivered over 1 billion treatments since inception and approximately 30 million treatments in 2024–25, reaching more than 21 million people. Direct delivery cost is approximately £1 to treat three people.

The charity's core technical offering is the integrated NTD programme stack: large-scale MDA implementation, country-level health systems support, and a research function that has produced proprietary tools including the Get All Treat (GAT) planning tool, the Schistosomiasis Practical and Precision Assessment (SPPA) for precision mapping, and the EPICYST transmission dynamics model. Through the Pediatric Praziquantel Consortium, the organisation contributed to the world's first pediatric schistosomiasis treatment, delivered in Uganda and Côte d'Ivoire. It also convenes the FGS Integration Group (FIG) to embed female genital schistosomiasis into reproductive and maternal health platforms.

Unlimit Health operates as a non-profit funded by philanthropic grants, government research and aid funding, and pharmaceutical company donations. Key institutional funders include the Bill & Melinda Gates Foundation, UK Research and Innovation (UKRI), the Medical Research Council (MRC), the UK Foreign, Commonwealth & Development Office (FCDO), and The END Fund, with in-kind drug donations from Merck, GSK, and Bayer. The organisation was granted Independent Research Organisation (IRO) status by UKRI in 2022 and rebranded from SCI Foundation to Unlimit Health around 2022–2023 to sharpen its elimination-focused positioning. The charity employs approximately 35 staff and is recommended by evaluator The Life You Can Save.

Name

Unlimit Health (formerly SCI Foundation)

Legal name

Unlimit Health

Website

https://unlimithealth.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Unlimit Health is a UK-registered charity (founded 2002, ~35 staff) that supports elimination of parasitic worm infections in 8 sub-Saharan African countries, delivering mass drug administration, health systems strengthening, and operational research funded by philanthropic grants, government donors, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Parasitic Disease Elimination Services

NAICS

Voluntary Health Organizations (813212), Social Assistance (624)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Communicable Disease Prevention & Control (HIV/AIDS, TB, Malaria, NTDs) (BPADAIAA)

akta.pro secondary industries

Health Systems Strengthening & Primary Care Development (HLAJAKAJ), Health Systems Strengthening & Global Health Technical Assistance (BPADAEAH), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• Neglected tropical diseases
• Parasitic disease elimination
• Mass drug administration
• Health systems strengthening
• Epidemiological research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Charitable Donations and Grants: As a UK-registered charity (registered company number 11775313, charity number 1182166), Unlimit Health raises funds from individual donors, institutional donors, and philanthropic foundations. Donations are used to fund mass drug administration programmes, research activities, and health systems strengthening in partner countries. The organisation was rated as highly cost-effective by The Life You Can Save, an independent evaluator.
2. Government and Institutional Grants: Funding from government bodies including UK Research and Innovation (UKRI), the UK Medical Research Council, and the UK Foreign, Commonwealth & Development Office (FCDO). Funding also comes from institutional donors such as the Bill & Melinda Gates Foundation, Merck, The END Fund, Bayer AG, CAF Canada, The Helen and Michael Brown Charitable Trust, and Giving What We Can.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels11 records

Core offering

Unlimit Health is an international charity that supports endemic countries in sub-Saharan Africa to eliminate parasitic diseases (primarily schistosomiasis and soil-transmitted helminthiasis) through mass drug administration programmes, health systems strengthening, monitoring and evaluation, and peer-reviewed research. The organisation works as an independent technical advisor to national ministries of health, providing financial and technical support for the delivery of preventive chemotherapy and integration of NTD services into national health systems.

Product overview

Unlimit Health (formerly SCI Foundation) is an international health organization—not a traditional software product company—focused on eliminating parasitic diseases through direct health intervention programs rather than a software platform. Its core 'product' is a comprehensive disease elimination service comprising mass drug administration (MDA) programs delivering treatments (praziquantel, albendazole, mebendazole) for schistosomiasis and soil-transmitted helminthiasis, supported by health systems strengthening, monitoring and evaluation, and research capabilities. These programs are delivered in partnership with ministries of health across sub-Saharan Africa. Key named offerings include: the Paediatric Praziquantel Consortium (partnership with pharmaceutical companies for child-friendly schistosomiasis treatment); research projects like ADOPT Programme, SUSTAIN Uganda, SNAPS, DRIVERS, and SOS; specialized tools including the Gap Assessment Tool (GAT); and intervention approaches including WASH integration and the One Health approach. The organization also provides training resources, research publications, and annual reports as knowledge products. Unlimit Health does not offer public software products, APIs, or cloud-based platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Mass Drug Administration (MDA) Programmes
• Health Systems Strengthening
• Monitoring and Evaluation Services
• Research and Technical Expertise
• Gap Assessment Tool (GAT)
• Paediatric Praziquantel Consortium
• SUSTAIN Uganda Research Project

Quantifiable outcome

• 30 million treatments supported in 2024-25, reaching 21.3 million people at risk in six countries
• +6 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

15 partnerships are on record, tiered major in-kind donor, core consortium, core coalition, core network, core partnership, advocacy partner, core implementation partner and patron/champion.

• GlaxoSmithKline (GSK)major in-kind donorOthersGSK donates albendazole (ALB), an essential treatment for lymphatic filariasis and intestinal worms, to ministries of health through WHO. The 12 billionth dose was delivered in Zanzibar in September 2024.
• Pediatric Praziquantel Consortiumcore consortiumStrategic or Co-development PartnerUnlimit Health is a member of the Pediatric Praziquantel Consortium, a not-for-profit international public-private partnership working on the development and delivery of a new schistosomiasis treatment tailored to pre-schoolers. Through this consortium, the world's first paediatric treatment for schistosomiasis was delivered to pre-school children in Uganda and Côte d'Ivoire.
• FGS Integration Group (FIG)core coalitionStrategic or Co-development PartnerUnlimit Health leads the FGS Integration Group (FIG), a coalition of organisations fighting to end female genital schistosomiasis. FIG coordinates action across sexual and reproductive health, HIV/HPV programmes, NTD initiatives, and WASH sectors to raise awareness, advocate for policy change, and promote scalable approaches.
• NTD NGO Network (NNN) — One Health Working Groupcore networkStrategic or Co-development PartnerUnlimit Health chairs the NTD NGO Network One Health working group, coordinating cross-sectoral approaches to NTD elimination with member organisations.
• Royal Society of Tropical Medicine and Hygiene (RSTMH) and Uniting to Combat NTDscore partnershipStrategic or Co-development PartnerUnlimit Health's Dr Gabrielle Laing worked with RSTMH and Uniting to Combat NTDs to develop recommendations on One Health for the G7 and world leaders, surveying 137 professionals from human, animal, and environmental health sectors.
• International Coalition for Advocacy on Nutrition (ICAN)advocacy partnerStrategic or Co-development PartnerUnlimit Health contributes to UK nutrition policy and advocacy through ICAN, linking parasitic disease control with nutrition programmes and international development policy.
• Ministry of Health, Zanzibarcore implementation partnerOthersLong-standing partnership with Zanzibar's Ministry of Health achieved a milestone with the 12 billionth dose of albendazole delivered. Reduced schistosomiasis prevalence from 50% to under 2% over the partnership period. Partnership spans over two decades of country-owned programme delivery.
• Ministry of Health, Ugandacore implementation partnerOthersPartnership with Uganda's Ministry of Health to deliver treatments for schistosomiasis, support the world's first paediatric praziquantel pilot, integrated child health days, and pork tapeworm research (SUSTAIN project).
• Ministry of Health, Côte d'Ivoirecore implementation partnerOthersPartnership with Côte d'Ivoire's Ministry of Health to support mass drug administration treatments and pilot the world's first paediatric treatment for schistosomiasis for pre-school children.
• Ministry of Health, Madagascarcore implementation partnerOthersPartnership with Madagascar's Ministry of Health to support delivery of mass drug administration treatments for schistosomiasis and intestinal worms.
• Ministry of Health, Mauritaniacore implementation partnerOthersChoose to Treat appeal secured treatment for 600,000 people in Mauritania through partnership with the Ministry of Health, facilitated by a workshop to explore increasing national investment in NTD services.
• Ministry of Health, Tanzaniacore implementation partnerOthersPartnership with Tanzania's Ministry of Health to support delivery of treatments in Mwanza region through mass drug administration campaigns.
• Ministry of Health, Democratic Republic of Congocore implementation partnerOthersPartnership with DRC's Ministry of Health to support delivery of treatments for schistosomiasis and soil-transmitted helminthiasis.
• Ministry of Health, Ethiopiacore implementation partnerOthersPartnership with Ethiopia's Ministry of Health to support delivery of treatments for parasitic diseases through mass drug administration.
• Her Royal Highness the Duchess of Edinburghpatron/championOthersHRH the Duchess of Edinburgh attended the ceremony for the delivery of the 12 billionth dose of albendazole in Zanzibar in September 2024, highlighting Unlimit Health's enduring partnership with the Zanzibar Ministry of Health.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• RTI International: Implements the USAID-funded ENVISION and Act to End NTDs programmes, providing technical assistance to ministries of health for NTD elimination including schistosomiasis and STH; directly comparable delivery model and end-market.
• Sightsavers: International NGO that supports mass drug administration for NTDs across sub-Saharan Africa and other endemic regions, including deworming and schistosomiasis programmes, with similar ministry-of-health technical-advisor model and donor-funded charity structure.
• The END Fund: Private philanthropy initiative dedicated to ending neglected tropical diseases; directly funds NTD MDA and country programmes including schistosomiasis and STH, sitting at the same intersection of philanthropy, MoH partnerships, and NTD elimination as Unlimit Health.
• Helen Keller International: Global health nonprofit with established NTD programmes including deworming and trachoma elimination, partnering with ministries of health in sub-Saharan Africa; similar size, charity-funded operating model, and integrated disease-plus-nutrition programming.
• Drugs for Neglected Diseases Initiative (DNDi): Global not-for-profit R&D organisation developing and delivering new treatments for neglected diseases; comparable in mission and charity-funded model, with parallel work on schistosomiasis treatments and paediatric formulations through public-private partnerships.
• Malaria Consortium: International NGO delivering integrated community-based health programmes including seasonal malaria chemoprevention and NTD interventions such as soil-transmitted helminthiasis treatment across sub-Saharan Africa, using comparable MoH-partnership and school-based delivery models.

Others

• World Vision: Large international NGO with NTD, WASH and community health programming in many of the same sub-Saharan African countries as Unlimit Health; adjacent rather than direct competitor, but a recurring co-funder and operational presence in the same geography.

Broad incumbents

• The Carter Center: Established NGO with longstanding NTD elimination programmes across Africa including schistosomiasis and STH, alongside broader health and peace programming; considerably larger and more diversified than Unlimit Health but directly comparable in MoH-partnered MDA delivery.
• FHI 360: Implements USAID's Act to End NTDs | East programme and broader global health portfolios across sub-Saharan Africa; comparable donor mix (USAID, foundations) and ministry-of-health technical-assistance model, though FHI 360 has a substantially broader portfolio.
• Task Force for Global Health: Significantly larger organisation housing multiple NTD-focused programmes including the Mectizan Donation Program and Children Without Worms; operates at greater scale and broader scope than Unlimit Health, with overlapping donor base and disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/unlimit_health
• YouTubeyoutube.com/channel/UCD0ypGr5wpjKsw7yCuX5e4Q
• Facebookfacebook.com/unlimithealthuk
• LinkedInlinkedin.com/company/unlimithealth
• Instagraminstagram.com/unlimithealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unlimit Health (formerly SCI Foundation)